Keywords: Volume Perfusion CT; Maximum slope; Deconvolution analysis; Cerebral vasospasm; Subarachnoid hemorrhage; ACA; Anterior cerebral artery; AUC; Areas Under the Curve; CBF; cerebral blood flow; CBV; cerebral blood volume; DC; Deconvolution model; DCI; delayed
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ADAMTS13; disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; aHUS; atypical hemolytic uremic syndrome; BU; Bethesda units; CF; complement factor; CFHR; complement factor H-related; HUS; hemolytic uremic syndrome; iTTP; auto
Keywords: TIC; time-intensity curve; CEUS; contrast-enhanced ultrasound; US; ultrasound; FNA; fine needle aspiration; RV; relative values; PI; peak intensity; RT; rise time; TTP; time to peak; MSCWI; the maximum slope coefficient of wash-in; MSCWO; the maximum slop
Keywords: ADAMTS13; TTP; Complement-mediated HUS; Pregnancy; Thrombotic microangiopathies;
Keywords: metastatic breast cancer; MBC; lobaplatin and gemcitabine; GL; lobaplatin and vinorelbine; NL; cisplatin and gemcitabine; GP; cisplatin and vinorelbine; NP; progression-free survival; PFS; overall survival; OS; response rate; RR; platinum-based compounds;
Keywords: Cerebral bypass; Flow 800; Hyperperfusion syndrome; BFI; Blood flow index; DLCFA; Descending lateral circumflex artery; EC-IC; Extracranial-to-intracranial; HPS; Hyperperfusion syndrome; ICG; Indocyanine green; ICG-BFA; Indocyanine green-based flow anal
Keywords: Impaired insulin signaling; TTP; Loss of ovarian function; Chemokines; Adipose tissue; ARE; adenylate uridylate-rich element; AT; adipose tissue; ATM; adipose tissue macrophage; BMM; bone marrow-derived macrophage; DIO; diet-induced obesity; GRO-α; grow
Keywords: aHUS; atypical hemolytic uremic syndrome; AP; alternative pathway; C3; complement component 3; C5; complement component 5; C3G; C3 glomerulopathy; CFB; complement factor B; CFH; complement factor H; CFI; complement factor I; COMS; complement serology pane
Keywords: IFN; interferon; TMA; thrombotic microangiopathy; HUVECs; human umbilical vein endothelial cells; IFNAR; IFN-α/β receptor; JAKs; Janus kinases; STAT; signal transducer and activator of transcription; mAb; monoclonal antibody; VEGF; vascular endothelial
Keywords: AE; adverse event; AUC; area under the curve; CI; confidence interval; Cmax; maximum concentration; HCC; hepatocellular carcinoma; HR; hazard ratio; OS; overall survival; PK; pharmacokinetic; PVA; polyvinyl alcohol; TTP; time to progression; W/O; water-in
Keywords: ABS; absenteeism; BSC; balanced scorecard; Ci; confidence interval; Cl; confidence level; CLT; central limit theorem; CPU; cost per unit; D/1000; defects per thousand; DOS; delivery operating system; FA; factor analysis; FC; fixed cost; FTT; first time th
Keywords: 5FU; 5-fluorouracil; 95%CI; 95% confidence interval; AA; amino acid; AFP; alpha fetoprotein; AML; actue myeloid leukemia; Ang2; angiopoietin 2; ATP; adenosine triphosphate; BCLC; Barcelona-Clinic Liver Cancer classification; BSC; best supportive care; CAP
Keywords: PSS; pediatric severe sepsis; MODS; multiple organ dysfunction syndrome; PE; plasma exchange; TAMOF; thrombocytopenia associated multiple organ failure; TTP; thrombotic thrombocytopenic purpura; CHA; Children's Hospital Association; PHIS; Pediatric Health
Keywords: AE; adverse event; ADR; adverse drug reaction; ANC; absolute neutrophil count; CI; confidence interval; CR; complete remission; CTCAE; common terminology criteria for adverse events; DEX; dexamethasone; ECOG; eastern cooperative oncology group; eCRF; elec
Keywords: Atypical hemolytic uremic syndrome; Complement; Eculizumab; Terminal complement inhibitor; Thrombotic microangiopathy; AH50; Alternative pathway function; TMA; Thrombotic microangiopathy; HUS; Hemolytic uremic syndrome; aHUS; Atypical HUS; LDH; Lactate de
Keywords: Ischemic penumbra; Ischemic threshold; Perfusion; Thrombolysis; Endovascular Therapy; ADC; Apparent diffusion coefficient; ASL; Arterial spin labeling; ATP; Adenosine triphosphate; CBF; Cerebral blood flow; CBV; Cerebral blood volume; CEST; Chemical excha
Keywords: AGD; anogenital distance; AHR; aryl hydrocarbon receptor; AMH; anti-Müllerian hormone; AR; androgen receptor; BPA; bisphenol A; CB-138; 2,2â²,3,4,4â²,5â² -hexachlorobiphenyl; CB-153; 2,2â²,4,4â²,5,5â²-hexachlorobiphenyl; DBP; di-n-butyl phthalate;
Keywords: DLBCL; diffuse large B-cell lymphoma; R-CHOP; rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; NHL; non-Hodgkin lymphoma; GEP; gene expression profiling; COO; cell-of-origin; GCB; germinal center B-cell; ABC; activated B-cell; PMBL;
Keywords: cough; CT; mycobacteria; tuberculosis; CayeCoM; Cayetano Cough Monitor; CXR; chest radiography; HR; hazard ratio; MD; mean difference; MODS; microscopic observation drug susceptibility; RR; rate ratio; TTP; time to positivity;
Keywords: LV; (left ventricle); ICC; (Intraclass correlation coefficient); TTP; (time to peak); Rotational mechanics; Neonatal physiology; Cardiac function; Normative data; Echocardiography;
Keywords: aHUS; HUS; kidney; monoclonal gammopathy; M protein; thrombotic microangiopathy; TTP;
Keywords: AH/AL; heavy/light chain amyloidosis; AL; immunoglobulin light chain amyloidosis; ALL; localized immunoglobulin light chain amyloidosis; BSC; best supportive care; DMSO; dimethyl sulfoxide; IFE; immunofixation; MALT; mucosa-associated lymphoid tissue; MGU
Keywords: FDA; Food and Drug Administration; MEK; mitogen-activated protein kinase kinase; MRI; magnetic resonance imaging; NF1; neurofibromatosis type 1; OPPN; orbital-periorbital plexiform neurofibroma; PN; plexiform neurofibroma; TTP; time to progression;
Keywords: prostatic hyperplasia; laser therapy; learning curve; mentors; urinary incontinence; BPH; benign prostatic hyperplasia; CD; case difficulty; GMP; grossly multinodular prostate; HoLEP; holmium laser enucleation of prostate; LCC; learning curve characteriza
Keywords: Ala; alanine; Arg; arginine; Asn; asparagine; Asp; aspartic acid; Cys; cysteine; Gln; glutamine; Glu; glutamic acid; Gly; glycine; His; histidine; Ile; isoleucine; Leu; leucine; Lys; lysine; Met; methionine; Phe; phenylalanine; Pro; proline; Ser; serine;
Keywords: CEUS; contrast-enhanced ultrasound; BI-RADS; breast imaging reporting and data system; RT; rising time; PI; peak intensity; MTT; mean transit time; AUC; area under the curve; WIS; wash-in slope; TTP; time to peak; ROC; receiver operating characteristic; B
Keywords: ABI; ankle-brachial index; ccDSA; color-coded digital subtraction angiography; CFA; common femoral artery; DP; dorsalis pedis; DSA; digital subtraction angiography; FOV; field of view; PAD; peripheral arterial disease; PTA; percutaneous transluminal angio
Keywords: factor V Leiden mutation; hypercoagulable state; hyperhomocysteinemia; livedoid vasculopathy; protein C deficiency; protein S deficiency; thrombophilia; thrombosis; ulcers; warfarin necrosis; AB; atrophie blanche; APC; activated protein C; APS; antiphosph
Keywords: Atrial switch; Strain pattern analysis; Dyssynchrony; Cardiac resynchronization therapy; Right ventricle; Mustard; Senning; 18S; 18-segment; ADI-MD; Activation delay-induced mechanical dyssynchrony; CRT; Cardiac resynchronization therapy; FAC; Fractiona
Keywords: CI; confidence interval; CR; complete response; HBV; hepatitis B virus; HCC; hepatocellular carcinoma; IQR; interquartile range; LEM; Lipiodol and ethanol mixture; OS; overall survival; PFS; progression-free survival; TEA; transarterial ethanol ablation;
Keywords: AST; aspartate aminotransferase; BSA; body surface area; CI; confidence interval; CP; Child-Pugh; HCC; hepatocellular carcinoma; HR; hazard ratio; OS; overall survival; PVT; portal vein thrombosis; TTP; time to progression; TTT; time to toxicity; 90Y; ytt
Keywords: AA; accelerated approval; ALL; acute lymphoblastic leukemia; CCyR; complete cytogenetic response; CLL; chronic lymphocytic lymphoma; CML; chronic myeloid leukemia; CRC; colorectal carcinoma; CR; complete response; CRi; complete response with incomplete bl
Keywords: O3; ozone; OH; hydroxyl; H2O2; hydrogen peroxide; O; oxygen; NxOy; nitrogen oxides of different oxidation states; NOS; nitric oxide synthase; Ar; argon; He; helium; UV; ultraviolet; CAP; cold atmospheric plasma; ACP; atmospheric cold plasma; APP; cold atm
Keywords: ACGIH; American Conference of Industrial Hygienists; AP; acidification potential; ATP; aquatic toxicity potential; ATPE; aqueous two-phase extraction; CIP; cleaning in place; CO; carbon oxides; CO2; carbon dioxide; EDTA; ethylenediaminetetraacetic acid; E
Keywords: SBRT; stereotactic body radiation therapy; HCC; hepatocellular carcinoma; RECIST; response evaluation criteria in solid tumors; CTCAE; common terminology criteria for adverse events; LC; local control; OS; overall survival; PFS; progression-free survival;
Keywords: 320-row CT; CT perfusion; xenon CT; CVRC; TTP; automated ROI
Keywords: 3-AP; 3-aminopyridine-2-carboxaldehyde thiosemicarbazone; ATM; ataxia telangiectasia mutated; ATR; ataxia telangiectasia and Rad3-related protein; AMP/ADP/ATP; adenosine mono-, di-, and tri-phosphate; BLM; Bloom syndrome RecQ helicase-like; BRAF; V-raf mu
Keywords: ApIS; apical inferoseptal; BIS; basal inferoseptal; MIS; mid inferoseptal; AVC; aortic valve closure time; CRT; cardiac resynchronization therapy; SRS; septal rebound stretch; SS; systolic strain; STE; speckle tracking echocardiography; TTP; time to peak
Keywords: AFP; alpha fetoprotein; HBsAg; hepatitis B surface antigen; HCC; hepatocellular carcinoma; TTP; time to progression;
Keywords: Surrogate outcome; Colorectal cancer; PFS; TTP; Tumor response; Health technology assessment;
Keywords: AMPK; AMP-activated protein kinase; ASK1; apoptosis signal-regulating kinase 1; Atg; autophagy-related; ARE; AU-rich element; AUF; ARE RNA binding protein; BRF; butyrate response factor; CaMK; Ca2Â +/calmodulin-dependent protein kinase; CUGBP; CUG-binding
Keywords: AFE; amniotic fluid embolism; DIC; disseminated intravascular coagulation; HELLP; hemolysis, elevated liver enzymes, and low platelets; HUS; hemolytic uremic syndrome; LDH; lactate dehydrogenase; MMR; maternal mortality rate; OHSS; ovarian hyperstimulatio
Keywords: TAMOF; AKI; TTP; HUS; DIC; ADAMTS-13; VWF; Platelet;
Keywords: Glioblastoma; Treatment; Review; Pharmacology; Targeted therapy; Stem cell; AKT; protein kinase B; BBB; blood-brain barrier; BCNU; carmustin; CCNU; lomustin; c-MET; hepatocyte growth factor receptor; EGF(R); epidermal growth factor (receptor); EGFRvIII; e
Keywords: Pyrimidine biosynthesis; Orotidine monophosphate decarboxylase; Ligand-enzyme interactions; Antimalarial agents; BMP; barbituric acid ribosyl 5â²-monophosphate (6-hydroxy UMP); CTP; cytidine 5â²-triphosphate; dCTP; deoxycytidine 5â²-triphosphate; HMOA;
Keywords: Postpartum; TTP; TMA; ADAMTS13; HELLP
Keywords: TTP; Therapeutic apheresis; Pregnancy;
Keywords: HCC; hepatocellular carcinoma; TTP; time to progression; NTUH; National Taiwan University Hospital; OS; overall survival; BCLC; Barcelona Clinic Liver Cancer; CLIP; Cancer of the Liver Italian Program; ECOG PS; Eastern Cooperative Oncology Group performan
Keywords: CI; confidence interval; EASL; European Association for the Study of the Liver; HCC; hepatocellular carcinoma; PVT; portal vein thrombosis; TIPS; transjugular intrahepatic portosystemic shunt; TTP; time to progression; 90Y; yttrium-90;
Keywords: AIHA; autoimmune hemolytic anemia; ASH; American Society of Hematology; CLL; chronic lymphocytic leukemia; CMV; cytomegalovirus; CVID; common variable immunodeficiency; GPRD; General Practice Research Database; DIC; disseminated intravascular coagulation;